Comment from Health Innovation Alliance

Summary: The Health Innovation Alliance (HIA), a coalition of healthcare stakeholders, supports the FDA's risk-based approach to regulating AI in drug and biological products. They argue that the FDA should use existing authorities to streamline regulatory processes, balance safety with innovation, and invest in AI to improve healthcare efficiency and address provider burnout.